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Molecular Imaging of Matrix
Metalloproteinase in Atherosclerotic Lesions
Resolution With Dietary Modification and Statin Therapy
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D. Scott Edwards, PHD,† Jun Zhou, MD,* Padmaja Yalamanchili, PHD,† Michael Azure, PHD,†
Ai Fujimoto, MD, PHD,* Satoshi Isobe, MD, PHD,* Yuji Matsumoto, MD, PHD,*
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Navneet Narula, MD,* Artiom Petrov, PHD,* Jagat Narula, MD, PHD, FACC*
Irvine, California; North Billerica, Massachusetts; Groningen, the Netherlands; and Tokyo, Japan
Objectives This study sought to evaluate the feasibility of noninvasive detection of matrix metalloproteinase (MMP) activity
in experimental atherosclerosis using technetium-99m–labeled broad matrix metalloproteinase inhibitor (MPI)
and to determine the effect of dietary modification and statin treatment on MMP activity.
Background The MMP activity in atherosclerotic lesions contributes to the vulnerability of atherosclerotic plaques to rupture.
Methods Atherosclerosis was produced in 34 New Zealand White rabbits by balloon de-endotheliazation of the abdominal
aorta and a high-cholesterol diet. In addition, 12 unmanipulated rabbits were used as controls and 3 for blood clear-
ance characteristics. In vivo micro–single-photon emission computed tomography (SPECT) imaging was performed
after radiolabeled MPI administration. Subsequently, aortas were explanted to quantitatively measure percent in-
jected dose per gram (%ID/g) MPI uptake. Histological and immunohistochemical characterization was performed
and the extent of MMP activity was determined by gel zymography or enzyme-linked immunosorbent assays.
Results The MPI uptake in atherosclerotic lesions (n  18) was clearly visualized by micro-SPECT imaging; MPI uptake
was markedly reduced by administration of unlabeled MPI before the radiotracer (n  4). The MPI uptake was
also significantly reduced after diet withdrawal (n  6) and fluvastatin treatment (n  6); no uptake was ob-
served in normal control rabbits (n  12). The %ID/g MPI uptake (0.10  0.03%) in the atherosclerotic lesions
was significantly higher than the uptake in control aorta (0.016  0.004%, p  0.0001). Uptake in fluvastatin
(0.056  0.011%, p  0.0005) and diet withdrawal groups (0.043  0.011%, p  0.0001) was lower than
the untreated group. The MPI uptake correlated with immunohistochemically verified macrophage infiltration
(r  0.643, p  0.0001), and MMP-2 (r  0.542, p  0.0001) or MMP-9 (r  0.578, p  0.0001) expression
in plaques.
Conclusions The present data show the feasibility of noninvasive detection of MMP activity in atherosclerotic plaques, and
confirm that dietary modification and statin therapy reduce MMP activity. (J Am Coll Cardiol 2008;52:
1847–57) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.048u
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fhe atherosclerotic plaques vulnerable to rupture frequently
how large lipid cores, positive vascular remodeling, thin
brous caps, and inflammatory infiltrates (1–3). Significant
rom the *University of California, Irvine School of Medicine, Irvine, California;
Bristol-Myers Squibb, Medical Imaging, North Billerica, Massachusetts; ‡Univer-
ity Medical Center, Groningen, the Netherlands; and the §Toho University School
f Medicine, Ohmori Hospital, Tokyo, Japan. The study was supported by National
nstitutes of Health grant RO1 (HL 078681) provided to Dr. Jagat Narula. The
uthors received MPI_RP805 from Bristol-Myers Squibb Imaging Co. (North Billerica,
assachusetts) and fluvastatin from Novartis and Tanabe Pharmaceuticals (Tokyo,
apan). Steven E. Nissen, MD, MACC, served as Guest Editor for this paper.a
Manuscript received January 11, 2008; revised manuscript received August 12,
008, accepted August 12, 2008.pregulation of matrix metalloproteinase (MMP) is ob-
erved in such plaques, which is directly related to the extent
f inflammation (4,5). The MMP expression and activation
ontributes to attenuation of fibrous caps and expansive
ascular remodeling, and therefore to the vulnerability of
laque to rupture (6–9); MMP expression is only minimally
bserved in stable plaques (10). Diet modification and statin
herapy have been shown to resolve the extent of inflam-
atory cell infiltration in the plaque and MMP activity
11–15). As such, MMP activity offers an important target
or molecular imaging for the detection of unstable plaques
nd for monitoring the effects of therapeutic interventions.
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MMP Imaging in Atheroma December 2, 2008:1847–57Recently, a fluorescent MMP
substrate has been used for opti-
cal imaging of atherosclerotic
plaques in mice (16), which gets
cleaved in the presence of active
MMP expression and the fluo-
rescent fragment is trapped to
become amenable to imaging.
In the present study, we used a
technetium-99m–labeled ma-
trix metalloproteinase inhibitor
(MPI) that binds to a variety of
active MMP family members. It
has been hypothesized (17–19)
that the extent of MPI uptake
would offer a precise estimate of
MMP activity in the atheroscle-
rotic lesions noninvasively.
Methods
he atherosclerotic lesions were induced experimentally in
ew Zealand White (NZW) rabbits by balloon de-
ndothelialization of the abdominal aorta followed by a
igh-fat and high-cholesterol (HC) diet. After intravenous
dministration of technetium-99m–labeled MPI, noninva-
ive imaging of the radiotracer uptake was performed by
icro–single-photon emission computed tomography
SPECT)/micro-computed tomography (CT) system. The
nimals were killed after in vivo imaging, and aortas were
xplanted for ex vivo imaging. Thereafter, the quantitative
PI uptake was determined by gamma counting of serially
ectioned aortic tissue specimens. Quantitative MPI uptake
as then compared with immunohistochemically verified
acrophage prevalence and MMP-2 and -9 expression in
he aortic specimens. The MPI uptake was also correlated
ith the MMP-2 and -9 activity in tissue specimens
easured by enzyme-linked immunosorbent assay or by gel
ymography. The impact of dietary modification and statin
herapy was investigated by measuring a change in the MPI
ptake in the additional groups of atherosclerotic animals.
lassification of study animals. In the present study,
oninvasive radionuclide MPI imaging was performed for
he detection of MMP in 49 NZW rabbits (Table 1). Of
therosclerosis and Control Animal Groups and Nature of Intervent
Table 1 Atherosclerosis and Control Animal Groups and Nature
Group
Balloon
De-Endothelialization
High-Cholesterol
Diet Interv
Disease control   —
Treatment control   (all 4 months) —
Statin intervention   (all 4 months) Fluvastatin (4
Diet withdrawal   (first 3 months) Normal chow
Tracer control   (all 4 months) —
Blood clearance   —
Abbreviations
and Acronyms
%ID/g  percent total
injected dose per gram of
tissue
CT  computed
tomography
HC  high cholesterol
MMP  matrix
metalloproteinase
MPI  matrix
metalloproteinase inhibitor
NZW  New Zealand White
PBS  phosphate-buffered
saline
SMC  smooth muscle cell
SPECT  single-photon
emission computed
tomographyPI  matrix metalloproteinase inhibitor.hese, 34 rabbits were subjected to balloon de-endothelization
f their abdominal aorta followed by 4 months of hypercho-
esterolemic diet for induction of experimental atheroscle-
otic lesions. Of the remaining 15 unmanipulated rabbits
ed normal chow for 4 months, 12 were used for MPI
maging as disease controls and 3 for conducting a blood
learance study. Of the 34 atherosclerotic rabbits, 18 re-
eived an uninterrupted cholesterol diet for all 4 months
treatment or positive control group), 6 received fluvastatin
in addition to an HC diet) in the fourth month (statin
roup), and 6 rabbits were returned to normal chow in the
ast month (diet withdrawal group) after receiving 3 months
f an HC diet. The remaining 4 atherosclerotic animals
eceived cold (unlabeled) MPI before radiotracer adminis-
ration to evaluate the specificity of radiotracer uptake.
xperimental atherosclerosis model. Male NZW rabbits
2.5 to 3.5 kg, Western Oregon Breeding Laboratories,
hilomoth, Oregon) were started on a high-fat, HC diet
ontaining 0.5% cholesterol and 6% peanut oil. One week
ater, balloon de-endothelialization of the abdominal aorta
as performed with a 4-F Fogarty embolectomy catheter
12-040-4F, Edwards Lifesciences LLC, Irvine, California)
s described previously (20). Briefly, animals were anesthe-
ized with a mixture of ketamine and xylazine (100 mg/ml,
0:1 vol/vol; 1.5 to 2.5 ml subcutaneously). The right
emoral artery was surgically exposed, and an embolectomy
atheter was introduced through an arteriotomy site and
dvanced in the aorta up to the level of the diaphragm. The
atheter was inflated to 3 psi and pulled antegrade to the
ifurcation of aorta for endothelial denudation; 3 such
enudation passes were made. After removing the catheter,
he femoral artery was ligated, the incision site was closed,
nd the animals were returned to cages. The HC diet was
ontinued for 16 more weeks. In 6 animals of the diet
ithdrawal group, normal chow was used in the last 4 of 16
eeks. In the 6 animals of the statin treatment group,
uvastatin (1 mg/kg orally, once per day, kind gift from
ovartis Pharmaceuticals, Tokyo, Japan) was given for
he last 4 of 16 weeks, as the animals continued to receive
he HC diet. Blocking experiments were performed to
valuate the specificity of radiotracer for MMP. For this
urpose, cold MPI was administered in 4 doses (0.02, 0.5,
.0, and 2.0 mg/kg) intravenously 30 min before radiotracer
dministration for radionuclide imaging. This protocol
terventions
n Tracer Purpose
12 MPI Negative control
18 MPI Positive control
nth) 6 MPI Effect of fluvastatin prescription
onth) 6 MPI Effect of diet modification
4 Cold MPI before MPI imaging Evaluation of specificity of MPI
3 MPI Tracer half-lifeions
of In
ention
th mo
(4th m
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December 2, 2008:1847–57 MMP Imaging in Atheromaollows the Guidelines for the Care and Use of Laboratory
nimals established by the National Institutes of Health
NIH Publication No. 85-23, revised 1996) and was ap-
roved by the Institutional Laboratory Animal Care and
se Committee at the University of California, Irvine.
argeting agent and radiolabeling. The targeting radio-
racer, MPI, used in the present study comprises a techne-
ium-99m–labeled broad-spectrum MMP-inhibiting mac-
ocyclic compound, RP-805 (a kind gift from the Research
nd Development division of Bristol-Myers Squibb Imag-
ng Inc., North Billerica, Massachusetts). The structure of
PI has been previously reported (21,22) and is shown in
igure 1. A portion of this compound binds to the exposed
atalytic domain of MMP. On the basis of the enzymatic
ssays, MPI binds specifically to a broad range of active
MP and not to other proteases (Fig. 1), and shows an
nzyme inhibitory profile (IC50) of 6.5, 14, 6.4, 7.4,
6.0, 7.3, 27, and 95 nM for MMP-2, -3, -7, -9, -12, and
13, and ADAM-10 and -17, respectively. For radiolabel-
ng of MPI, the contents of the vehicle vial were dissolved
n 0.5 ml of 0.9% sterile saline, and the clear solution was
ransferred to a vial containing 25 to 35 g MPI. The
ixture was incubated for 10 min, and then90 mCi/ml of
c-99m pertechnetate was added to the solution. The
eaction vial was heated at 100°C for 10 min. Finally,
igh-pressure liquid chromatography analysis was per-
ormed to check the radioefficiency, which showed a prod-
Figure 1 Structure and Specificity of MPI
(A) Structure of matrix metalloproteinase inhibitor (MPI) (Tc-99m–MPI). (B) Proof o
radioimaging binds only to the active MMP. In this radioimmunoassay, radiolabelect peak of 97%. The radiotracer was intravenously
dministered to all animals through the marginal vein of the
ight ear.
adionuclide imaging, protocol, and data collection.
adionuclide imaging was performed immediately after
adiotracer administration and 4 h later using a dual-head
icro-SPECT gamma camera coupled with micro-CT
X-SPECT, Gamma Medica, Inc., Northridge, California).
he SPECT images of the aorta were acquired in a 64 64
atrix, 32 stops at 20 s (at 0 h) or 120 s (at 4 h) per stop at
40 keV photopeak of Tc-99m with 15% windows using a
ow-energy, high-resolution parallel-hole collimator. After
PECT acquisition, a micro-CT scan was acquired without
aving to move the animal. The micro-CT used an X-ray
ube operating at 50 kVp and 0.6 mA. Images were captured
or 2.5 s per view for 256 views in 360° rotation. The
icro-CT images were transferred to a 256  256 matrix
nd micro-CT tomographic studies were fused, allowing
cintigraphic and anatomic information in all tomographic
cans in the 3 different spatial axes. After imaging, animals
ere killed with an overdose of sodium pentobarbital (120
g/kg). The aortas were harvested for ex vivo gamma
maging. The entire aorta was then segmented at 1-cm
ntervals, weighed, and gamma counted in an automatic
ell-type gamma counter (PerkinElmerWallac Inc., Gaith-
rsburg, Maryland) for calculation of the percent injected
PI dose per gram uptake in aortic tissue (%ID/g). Aorta
rinciple that the MPI used for
bound to active matrix metalloproteinase (MMP)-2 only.f the p
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MMP Imaging in Atheroma December 2, 2008:1847–57as then processed for histologic and immunohistochemical
haracterization, and for MMP activity assays.
lood clearance and biodistribution studies. In 3 unma-
ipulated normal rabbits, serial blood samples were drawn at
, 5, 15, 30, 60, 90, 120, 150, and 180 min to obtain the
lood clearance characteristic of the radiotracer. In addition,
issue samples of various organs were used for calculation of
he %ID/g tissue uptake to characterize the nontarget organ
iodistribution. To correct for the radioactive decay and
ermit calculation of the concentration of radioactivity as a
raction of the administered dose, aliquots of the injected
ose were preserved and counted simultaneously.
istological and immunohistochemical characterization.
ne-half of every 1-cm aortic segment was snap frozen and
he other one-half was fixed overnight with 4% paraformal-
ehyde in phosphate-buffered saline (PBS, pH 7.4 at 4°C.
ixed tissue was stored in PBS/0.02% sodium azide (NaN3)
t 4°C until use. Each segment was subdivided into 3
quidistant sections, and dehydrated in a graded series of
thanol for paraffin embedding for further processing. Par-
ffin blocks were cut in 4-m-thick sections on a microtome
nd floated on a water bath containing deionized water
43°C). The sections were then transferred to reagent-
reated slides (Vectabond, SP-1800, Vector Labs, Burlin-
ame, California), allowed to dry overnight, and stored at
°C. To perform routine histologic studies, tissue sections
ere deparaffinized in xylene and graded series of ethanol.
issue sections were stained with Movat pentachrome
tains, and hematoxylin and eosin.
In atherosclerotic lesions, smooth muscle cells (SMC)
ere identified using a primary antibody against -actin
sotypes (MAB1420, 1:10,000, R&D Systems, Minneapo-
is, Minnesota) and macrophages were localized using a
AM-11 marker (M 0633, 1:3,000, DAKO, Carpinteria,
alifornia). For MMP characterization, monoclonal
MP-2 (gelatinase-A, IM53, 1:52,000, Calbiochem, Gibbs-
own, New Jersey); and monoclonal MMP-9 (gelatinase-B,
M37, 1:15,000, Calbiochem) antibodies were used. Immu-
ohistochemical staining was performed using standard
taining procedures as below. Tissue sections were deparaf-
nized, washed, and placed in a water bath for antigen
etrieval at 90°C in (Vector Labs) antigen unmasking
olution (H-3300) for 25 min followed by cooling to room
emperature for 20 min. For -actin and RAM-11 staining,
ections were rinsed with PBS several times, and endoge-
ous peroxidase quenched with fresh 3% H2O2 for 5 min.
issue sections incubated in 2% immunoglobulin G–free,
rotease-free bovine serum albumin (001-000-161, Jackson,
est Grove, Pennsylvania) with 0.1% Triton X-100 in PBS
or 1 h to inhibit the nonspecific binding of primary
ntibody. Sections were incubated overnight with primary
ntibody at 4°C. After 3 washes, sections were subsequently
ncubated with biotinylated secondary antibody against the
orresponding species of primary antibodies for 1 h at room
emperature, followed by ABC treatment (PK-6100, Vector
abs). Primary and secondary antibodies were diluted in the wame bovine serum albumin–containing blocking solution
s described above. For staining of the MMP-2 and -9, the
ections were pre-treated in water bath at 90°C and incu-
ated with 0.005% pronase E for 10 min at room temper-
ture. After washing in Tris-buffered saline, the sections
ere incubated overnight with primary antibody at 4°C,
ashed in Tris-buffered saline containing Tween 20, and
reated with the catalyzed signal amplification II kit (DAKO)
ccording to the manufacturer’s instructions. Color reaction
as developed using a Novared substrate-chromogen sys-
em (SK-4800, red color, Vector Labs) and diaminobenzi-
ine kit (DAB, brown color, SK-4100, Vector Labs). The
ections were counterstained with Gill hematoxylin. Sec-
ions incubated in parallel without primary antibody were
sed as quality control for staining procedure. Immuno-
taining was examined (Zeiss Axiovert-200 microscope,
arl Zeiss, Thornwood, New York), images were acquired
Zeiss Axiocam high-resolution digital color camera, 1,300
1,030 pixels, and Axiovision 3.1 software, Thornwood,
ew York), and digital images were analyzed (Image-Pro
lus version 5.0, Media Cybernetics, Bethesda, Maryland).
he percent of immunopositive area (immunopositive area/
otal intimal area  100) was determined for all markers by
veraging several images per section that covered most to all
f the plaque regions. Tissue samples from all regions of
orta and all animals were analyzed so that %ID/g MPI
ptake and histologic severity of atherosclerotic lesions
epresented a broad spectrum, and allowed calculation of the
orrelation between MPI uptake and quantitative MMP
istribution. All quantitative comparisons for a given
arker were performed on sections stained simultaneously
er group. Digital images were obtained using the same
ettings, and the segmentation parameters were constant
ithin a range for a given marker and experiment.
MP activity assays. Zymography was performed for the
ssessment of MMP-9 activity. Frozen plaque tissues were
eighed and homogenized in 1 ml PBS containing 1%
riton X-100 and frozen overnight at70°C. The next day,
ondissolved fragments were removed by centrifugation at
2,000 rpm for 5 min and supernatant (with MMP)
ollected. The protein concentration was determined using
Lowry protein assay kit (Bio-Rad, Hercules, California).
or each sample, 20-g protein was loaded on 10% sodium
odecyl sulfate–polyacrylamide gel electrophoresis gel. The
amples were run at 100 V per manufacturer’s protocol
Novex, Carlsbad, California). After the run, the sodium
odecyl sulfate–polyacrylamide gel electrophoresis gel was
enatured in the zymogram renaturing buffer for 1 h,
ollowed by incubation in the developing buffer overnight.
he gel was stained with Coomassie Blue and destained
ith 30% methanol/10% glacial acetic acid. The white
ands with active MMP-9 were identified based on stan-
ards of purified recombinant activated MMP-9 and the
olecular size. The optical density of the MMP-9 bands
as quantified with ImageJ (Version 1.40, NIH, Bethesda,
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December 2, 2008:1847–57 MMP Imaging in Atheromaaryland) and expressed as a percentage of the control
MP-9 run on each gel sample.
The MMP-2 activity was measured by enzyme-linked
mmunosorbent assay using the Biotrak assay system (GE
ealthcare, Piscataway, New Jersey). Supernatant with
MP, obtained as described above, was used in the assay.
e incubated 200 g of plaque protein overnight in
6-well plates containing MMP-2 antibody. On the next
ay, the plate was washed 4 times and 50 l of the detection
eagent was added. The plate was then read in a plate reader
Bio-Rad) at 405 nm. The level of active MMP-2 was
uantified by using purified activated human MMP-2 as the
tandard.
tatistical analysis. All results are presented as the mean
D. To determine the statistical significance of differences
etween groups, 1-way analysis of variance was used; groups
ere compared independently using Fisher post-hoc least
ignificant difference analysis. The correlation between ra-
iolabeled MPI uptake and histological descriptors was
etermined by linear regression analysis. A value of p 
.05 was considered statistically significant.
esults
oninvasive imaging of MMP activity in atherosclerotic
esions. The Tc-99m–labeled MPI (6.9  0.18 mCi) was
dministered intravenously for radionuclide imaging of
therosclerotic lesions. Immediately after tracer administra-
ion, blood pool images were obtained by micro-SPECT,
hich showed an aorta in front of a vertebral column
ocalized by micro-CT image fusion. Serial image acquisi-
ion in the initial animals showed that the lesions could be
isualized best at 3 to 4 h after tracer administration in
therosclerotic animals on an uninterrupted HC diet (Fig.
). Initial blood pool images were observed similarly in
ontrol animals as well, but no tracer uptake in abdominal
orta was seen in these animals after 3 to 4 h (Fig. 2). The
PI uptake in delayed images was markedly reduced in the
iet withdrawal group and in those treated with fluvastatin
Fig. 2). After imaging, animals were killed and the aortas
ere harvested for ex vivo gamma imaging. Ex vivo images
f the explanted aorta showed intense MPI uptake in
bdominal region of the atherosclerotic animals receiving an
ninterrupted diet. Ex vivo images confirmed the in vivo
maging observations and correlated with gross distribution
f pathologic lesions. No uptake was observed in the aortas
btained from unmanipulated, disease control rabbits re-
eiving normal chow. The tracer uptake in ex vivo images
as markedly reduced in the diet withdrawal and statin
roups, again confirming the findings of in vivo imaging
Fig. 3). Maximum uptake was evident in the abdominal
ortic region. Atherosclerotic lesions also were observed in
he nondenuded arch and thoracic aortic regions in animals
eceiving an HC diet. As such, the radiotracer uptake in the
rch of the aorta and thoracic aorta was also higher in wnimals receiving an uninterrupted diet compared with
ontrol animals.
uantitative MPI uptake in aortic specimens and non-
arget organs. After ex vivo imaging, 1-cm segments of the
ntire aorta were individually weighed and gamma counted
or calculation of the %ID/g radio tracer uptake and the
arget-to-background uptake ratio. The MPI uptake in the
bdominal atherosclerotic lesions of the uninterrupted diet
roup (0.10  0.03%) was significantly higher than the
ptake in abdominal aortic specimens from the control
nimals (0.016  0.004%; p  0.0001). The accumulation
f MPI in atherosclerotic lesions was 6.3-fold greater than
n the control animals. The MPI uptake decreased by 45%
o 55% in the intervention groups; the quantitative uptake in
tatin (0.056  0.011%; p  0.0005) and diet withdrawal
0.043  0.011%; p  0.0001) groups was statistically
ignificantly lower compared with the uninterrupted diet
roup (Fig. 3). To evaluate the specificity of radiotracer
ptake for the MMP target, unlabeled MPI was adminis-
ered 30 min before the radiotracer. There was a dose-
elated decrease in MPI uptake. Cold MPI administered in
oses of 0.02, 0.5, 1.0, and 2.0 mg/kg reduced radiolabeled
PI uptake by 35%, 62%, 69%, and 86%, respectively.
adiolabeled MPI uptake after 2 mg/kg cold MPI was
lmost equivalent to radiolabeled MPI uptake in disease
ontrol normal rabbits (Fig. 3C). MPI uptake in various
ontarget organs was also evaluated. The kidney showed
he maximum radiation burden; %ID/g uptake in the
ortex, medulla, and urine was 2.5  0.4%, 0.11 
.04%, and 0.47  0.20%, respectively. All other organs
howed minimal burden.
athologic characterization of atherosclerotic lesions.
ne-half of every 1-cm aortic segment was processed for
istological analysis. Most of the atherosclerotic specimens
rom animals on an uninterrupted diet showed fibroathero-
atous lesions. The neointimal lesions showed a high
acrophage content, MMP-2 expression, and MMP-9
xpression and a low SMC prevalence (Fig. 4). The mac-
ophage content and the MMP expression were reduced
arkedly in the diet and statin intervention groups (Fig. 4).
he percent macrophage area in the uninterrupted diet
roup (17.30  8.17%) was significantly greater compared
ith the statin (5.77  2.59%; p  0.001) and diet
ithdrawal (2.16 0.73%; p 0.0001) groups (Fig. 5). On
he other hand, there was an increase in the SMC preva-
ence in the intervention groups, particularly in the statin-
reated group (Fig. 4). The SMC-positive area was signif-
cantly lower in the uninterrupted diet group (4.53 
.89%) compared with the statin (17.72  9.14%; p 
.0001) and diet withdrawal (9.60  4.92%; p  0.05)
roups (Fig. 5). Similar to macrophage prevalence, areas
ositive for MMP-2 and -9 were significantly greater in the
ninterrupted diet group (4.80  2.69% and 8.28  3.85%,
espectively) than in the statin (1.11  0.69%, p  0.005
nd 3.45  2.39%, p  0.005, respectively) and diet
ithdrawal (0.97  0.63%, p  0.0005 and 2.32  0.96, p
1852 Fujimoto et al. JACC Vol. 52, No. 23, 2008
MMP Imaging in Atheroma December 2, 2008:1847–57Figure 2 Radionuclide Imaging of Atherosclerotic Lesions
Images are presented in a 3  3 format in which 3 columns display transverse, sagittal, and frontal projections, and 3 rows display micro–computed tomography (CT),
micro–single-photon emission computed tomography (SPECT), and fusion images. The left set of 3 columns displays images immediately (0 h) after radiotracer adminis-
tration (representing blood pool image), and the right set of 3 columns displays images obtained at 4 h (representing tracer uptake in target tissue). Images obtained
(A) from an atherosclerotic rabbit on uninterrupted diet, (B) from a control unmanipulated animal (with no atherosclerotic lesions), (C) from a fluvastatin-treated animal,
and (D) after dietary modification. Blood pool (left) in all animals (A to D) can be observed (arrows) in front of vertebral column (as identified computed tomography and
fusion images) in the early images. However, in delayed images (right) obtained at 4 h, radiotracer is cleared from the blood pool and uptake represents target tissue
accumulation. Intense matrix metalloproteinase inhibitor (MPI) uptake is observed in an atherosclerotic animal on an uninterrupted diet (A). No MPI uptake is discern-
able in a control animal (B), statin-treated animal (C), or after diet modification (D).
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December 2, 2008:1847–57 MMP Imaging in Atheroma0.001, respectively) groups (Fig. 5). Regression analysis
howed a significant correlation between MPI uptake and
xpression of MMP-2 (r 0.542, p 0.0001) andMMP-9
r  0.578, p  0.0001) (Fig. 5). There was also a significant
irect relationship of MPI uptake with macrophage content (r
0.643, p 0.0001) but none with SMC content (r 0.082,
 NS) (Fig. 5) in atherosclerotic lesions.
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Figure 5 Correlation of Macrophage, SMC, MMP-2, and MMP-9 Positive Areas With Quantitative MPI Uptake
Macrophage (A), SMC (B), MMP-2 (C), and MMP-9 (D) positive areas are presented as mean  SD in uninterrupted diet (solid bars, n  18), fluvastatin (gray bars, n  6) and
diet withdrawal groups (lined bars, n  6) (above). Intervention groups showed a significant decrease in immunopositive areas for macrophage compared with the uninterrupted
diet group. In contrast, intervention groups showed a significant increase in immunopositive areas of SMC compared with the uninterrupted diet group. The MPI uptake corre-
lated (below) significantly with the macrophage-positive area, but no correlation with SMC is apparent. Percent immunopositive areas for MMP-2 (C) and MMP-9 (D) decreased
in intervention groups compared with the uninterrupted diet group. The MPI uptake correlated significantly with MMP-2 and -9 positive areas. Abbreviations as in Figure 4.
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ay address plaque vulnerability.
onclusions
he present data show that in vivo quantification of MMP
ctivity in atherosclerotic plaques is feasible by noninvasive
argeted imaging. The radiotracer uptake correlates with the
athologically verified expression of MMP-2 and -9 in the
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Figure 6 MMP-2 and -9 Activity in Tissue
Specimens From Various Animal Groups
(A) The matrix metalloproteinase (MMP)-2 activity, represented as the mean 
SD of 3 individual samples by enzyme-linked immunosorbent assay, shows sig-
nificantly higher levels in the uninterrupted diet group (solid bars, n  3) com-
pared with the fluvastatin (gray bars, n  3) and diet withdrawal (lined bars, n
 3) groups and control (open bars, n  3) animals. (B) The MMP-9 activity in
aortas obtained from various animal groups was evaluated by zymography. The
area of each band in gel zymograms was determined with ImageJ software to
provide the net area value, and the change in area was calculated in compari-
son to the control active MMP-9 run in each gel (percent). The histogram repre-
sents mean  SD of 3 separate experiments for each group. Results showed
high MMP-9 levels in the uninterrupted group and a reduction in the interven-
tion groups.laque. The imaging observations also have reconfirmedrevious observations that dietary modification and statin
reatment may substantially decrease MMP activity in
therosclerotic lesions.
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